Page last updated: 2024-08-21

d-alpha tocopherol and selegiline

d-alpha tocopherol has been researched along with selegiline in 79 studies

Research

Studies (79)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (8.86)	18.7374
1990's	46 (58.23)	18.2507
2000's	19 (24.05)	29.6817
2010's	6 (7.59)	24.3611
2020's	1 (1.27)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Berg, MJ; Collier, DS; Fincham, RW	1
Nag, D	1
Shoulson, I	5
Levivier, M; Przedborski, S	1
LeWitt, PA	3
Cotton, P	1
Landau, WM	1
Heikkila, RE; Sieber, BA; Terleckyj, I	1
Friedman, JH	1
Lewin, R	1
Merz, B	1
Grimes, JD; Hassan, MN; Thakar, JH	1
Gerlach, M; Riederer, P; Youdim, MB	1
Carter, J; Fahn, S; Gauthier, S; Goetz, CG; Golbe, LI; Jankovic, J; Koller, W; Lang, AE; McDermott, MP; Olanow, CW	1
Brady, J; Carter, J; Como, P; Growdon, J; Huber, S; Kanigan, B; Kieburtz, K; Landow, E; McDermott, M; Rudolph, A	1
Gatt, JA; Houghton, E; Mitchell, JD; Phillips, TM; Rostron, G; Shaw, IC; Whittington, J; Wignall, C	1
Calne, DB; Uitti, RJ; Vingerhoets, FJ	1
Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ	1
Olanow, CW	1
Ernesto, C; Growdon, J; Grundman, M; Klauber, MR; Sano, M; Schafer, K; Thal, LJ; Thomas, R; Woodbury, P	1
Andersen, JK; Jurma, OP; Wei, Q; Yeung, M	1
Heinonen, E; Mäki-Ikola, O	1
Cui, L; LeWitt, P; Oakes, D	1
Cotman, CW; Ernesto, C; Growdon, J; Grundman, M; Klauber, MR; Pfeiffer, E; Sano, M; Schafer, K; Schneider, LS; Thal, LJ; Thomas, RG; Woodbury, P	1
Drachman, DA; Leber, P	1
Oliveira, CR; Pereira, CM	1
Pincus, MM	1
Kilander, L; Ohrvall, M	1
Adelman, A	1
Jiménez-Jiménez, FJ; Molina, JA	1
Cummings, JL; Tom, T	1
Fahn, S; Kuskowski, MA; Vatassery, GT	1
Schneider, LS	1
Koller, WC	1
Cummings, JL	1
Sunderland, T; Tune, LE	1
Althaus, JS; Fici, GJ; VonVoigtlander, PF	1
Pryse-Phillips, W	1
Cathcart, S; Sachdev, P; Saharov, T	1
Grundman, M	1
Cummings, J; Fillit, H	1
Jacob, RF; Mason, RP; Olmstead, EG	1
Delanty, N; Praticò, D	1
Gerlach, M; Riederer, P; Sian, J	1
Fahn, S; Giladi, N; Jankovic, J; McDermott, MP; Przedborski, S; Stern, M; Tanner, C	1
Jamrozik, Z; Janik, P; Kwieciński, H; Opuchlik, A	1
Knoll, B; Knoll, J; Miklya, I	1
Sano, M	1
DeLaGarza, VW	1
Hatakeyama, Y; Nakano, N; Yoshida, T	1
Kitamura, S	1
Shen, ZX	1
Arya, P; Butler, R; Warner, J	1
Casarett, DJ; Hirschman, KB; James, BD; Joyce, CM; Karlawish, JH; Xie, SX	1
Alper, G; Caglayan, O; Duman, E; Irer, S; Yilmaz, C	1
Tariot, PN	1
Ames, D; Ritchie, C	1
Feldman, HH; Hsiung, GY	1
Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Stewart, T; Zhang, J	1
Auinger, P; Cain, KC; Cholerton, B; Ginghina, C; Liu, C; Shi, M; Zhang, J	1
Andreazza, AC; Berk, M; Dean, O; Kapczinski, F; Magalhães, PV	1
Auinger, P; Christine, CW; Green, R; Joslin, A; Yelpaala, Y	1
Hall, J; Johnson, L; Mason, D; O'Bryant, SE; Petersen, M; Zhang, F	1

Reviews

26 review(s) available for d-alpha tocopherol and selegiline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Parkinsonism treatment: Part III--Update. The Annals of pharmacotherapy, 1992, Volume: 26, Issue:2 Topics: Antioxidants; Dopamine Agents; Female; Fetal Tissue Transplantation; Humans; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline; Vitamin E	1992
[Current therapeutic approach in Parkinson disease]. Revue medicale de Bruxelles, 1992, Volume: 13, Issue:10 Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E	1992
Neuroprotective clinical strategies for Parkinson's disease. Annals of neurology, 1992, Volume: 32 Suppl Topics: Drug Therapy, Combination; Humans; Iron; Oxidation-Reduction; Parkinson Disease; Selegiline; Vitamin E	1992
Antioxidative therapeutic strategies for Parkinson's disease. Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648 Topics: Antioxidants; Double-Blind Method; Free Radical Scavengers; Humans; Parkinson Disease; Selegiline; Vitamin E	1992
Parkinson's disease update. Rhode Island medical journal, 1989, Volume: 72, Issue:11 Topics: Adrenal Medulla; Clinical Trials as Topic; Humans; Parkinson Disease; Selegiline; Vitamin E	1989
Prevention of progression of Parkinson's disease with antioxidative therapy. Progress in neuro-psychopharmacology & biological psychiatry, 1988, Volume: 12, Issue:2-3 Topics: Antioxidants; Humans; Parkinson Disease; Selegiline; Vitamin E	1988
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochemical pharmacology, 1995, Jun-29, Volume: 50, Issue:1 Topics: Animals; Humans; Nervous System Diseases; Parkinson Disease; Selegiline; Vitamin E	1995
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. Journal of neural transmission. Supplementum, 1994, Volume: 43 Topics: Clinical Trials as Topic; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Time Factors; Vitamin E	1994
Neuroprotection by anti-oxidant strategies in Parkinson's disease. European neurology, 1993, Volume: 33 Suppl 1 Topics: Antioxidants; Corpus Striatum; Dopamine; Humans; Monoamine Oxidase; Parkinson Disease; Reactive Oxygen Species; Receptors, Dopamine; Selegiline; Substantia Nigra; Vitamin E	1993
[Neuroprotective and neurorestorative therapy in Parkinson's disease]. Revista de neurologia, 1997, Volume: 25 Suppl 2 Topics: Antiparkinson Agents; Apoptosis; Brain Tissue Transplantation; Chelation Therapy; Corpus Striatum; Dopamine; Erythrocytes; Free Radicals; Gangliosides; Genetic Therapy; Glutathione Peroxidase; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Selegiline; Selenium; Vitamin E	1997
Neuroprotection for Parkinson's disease. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
New cholinergic therapies: treatment tools for the psychiatrist. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 13 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinergic Agents; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens; Female; Humans; Indans; Male; Piperidines; Selective Serotonin Reuptake Inhibitors; Selegiline; Tacrine; Vitamin E	1998
Do we have drugs for dementia? No. Archives of neurology, 1999, Volume: 56, Issue:6 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phytotherapy; Piperidines; Plants, Medicinal; Selegiline; Tacrine; Vitamin E	1999
Vitamin E and Alzheimer disease: the basis for additional clinical trials. The American journal of clinical nutrition, 2000, Volume: 71, Issue:2 Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Clinical Trials as Topic; Cognition Disorders; Humans; Lipid Peroxidation; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E	2000
Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. The American journal of medicine, 2000, Volume: 109, Issue:7 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Ascorbic Acid; Benzoquinones; Central Nervous System; Central Nervous System Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Free Radicals; Ginkgo biloba; Humans; Lipid Peroxidation; Neuroprotective Agents; Oxidation-Reduction; Phytotherapy; Plants, Medicinal; Selegiline; Ubiquinone; Vitamin E	2000
Is there neuroprotection in Parkinson syndrome? Journal of neurology, 2000, Volume: 247 Suppl 4 Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; Selegiline; Vitamin E	2000
Noncholinergic treatment options for Alzheimer's disease. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 9 Topics: Aged; Alzheimer Disease; Animals; Anticholesteremic Agents; Antioxidants; Behavioral Symptoms; Clinical Trials as Topic; Cognition Disorders; Estrogens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Patient Selection; Research Design; Selegiline; Vitamin E	2003
Pharmacologic treatment of Alzheimer's disease: an update. American family physician, 2003, Oct-01, Volume: 68, Issue:7 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Drug Monitoring; Estrogens; Ginkgo biloba; Humans; Neuroprotective Agents; Phytotherapy; Practice Guidelines as Topic; Selegiline; Vitamin E	2003
[Mild cognitive impairment]. Ryoikibetsu shokogun shirizu, 2003, Issue:40 Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Disease Progression; Humans; Psychiatric Status Rating Scales; Selegiline; Severity of Illness Index; Vitamin E	2003
[Prognosis in Alzheimer's disease]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; Indans; Mental Processes; Piperidines; Prognosis; Risk; Selegiline; Survival Rate; Time Factors; Vitamin E	2004
Dementia. Clinical evidence, 2004, Issue:11 Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E	2004
Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Transfer; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Selegiline; Severity of Illness Index; Treatment Outcome; Vitamin E	2006
Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:15 Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine; Selegiline; Severity of Illness Index; Vitamin E	2008
Antioxidant treatments for schizophrenia. The Cochrane database of systematic reviews, 2016, Feb-05, Volume: 2 Topics: Acetylcysteine; Allopurinol; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Dehydroepiandrosterone; Drug Therapy, Combination; Free Radical Scavengers; Ginkgo biloba; Humans; Oxidative Stress; Randomized Controlled Trials as Topic; Schizophrenia; Selegiline; Vitamin E; Vitamins	2016

Trials

28 trial(s) available for d-alpha tocopherol and selegiline

Article	Year
An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. European neurology, 1992, Volume: 32 Suppl 1 Topics: Activities of Daily Living; Adult; Aged; Disability Evaluation; Double-Blind Method; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1992
Antioxidative therapeutic strategies for Parkinson's disease. Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648 Topics: Antioxidants; Double-Blind Method; Free Radical Scavengers; Humans; Parkinson Disease; Selegiline; Vitamin E	1992
Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta neurologica Scandinavica. Supplementum, 1991, Volume: 136 Topics: Adult; Aged; Brain; Disability Evaluation; Drug Therapy, Combination; Humans; Middle Aged; Monoamine Oxidase; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1991
DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Archives of neurology, 1989, Volume: 46, Issue:10 Topics: Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline; Vitamin E	1989
Effect of deprenyl on the progression of disability in early Parkinson's disease. The New England journal of medicine, 1989, 11-16, Volume: 321, Issue:20 Topics: Activities of Daily Living; Clinical Trials as Topic; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline; Vitamin E	1989
Parkinson's disease update. Rhode Island medical journal, 1989, Volume: 72, Issue:11 Topics: Adrenal Medulla; Clinical Trials as Topic; Humans; Parkinson Disease; Selegiline; Vitamin E	1989
Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Adult; Aged; Antioxidants; Canada; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline; United States; Vitamin E	1989
Drug trial for Parkinson's. Science (New York, N.Y.), 1987, Jun-12, Volume: 236, Issue:4807 Topics: Clinical Trials as Topic; Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1987
Adrenal-to-brain transplants continue as neurologists test two new drugs. JAMA, 1987, Aug-21, Volume: 258, Issue:7 Topics: Adrenal Glands; Caudate Nucleus; Clinical Trials as Topic; Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1987
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Archives of neurology, 1995, Volume: 52, Issue:6 Topics: Adult; Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors; Selegiline; Sex Factors; Vitamin E	1995
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Archives of neurology, 1995, Volume: 52, Issue:3 Topics: Adult; Aged; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Selegiline; Vitamin E	1995
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology, 1994, Volume: 44, Issue:9 Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline; Vitamin E	1994
Cu/Zn superoxide dismutase free radicals, and motoneuron disease. Lancet (London, England), 1993, Oct-23, Volume: 342, Issue:8878 Topics: Ceruloplasmin; Double-Blind Method; Free Radicals; Glutathione; Glutathione Peroxidase; Humans; Motor Neuron Disease; Placebos; Selegiline; Superoxide Dismutase; Vitamin E	1993
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The New England journal of medicine, 1993, Jan-21, Volume: 328, Issue:3 Topics: Activities of Daily Living; Arrhythmias, Cardiac; Follow-Up Studies; Humans; Parkinson Disease; Psychiatric Status Rating Scales; Psychomotor Performance; Regression Analysis; Selegiline; Vitamin E	1993
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer disease and associated disorders, 1996,Fall, Volume: 10, Issue:3 Topics: Aged; Alzheimer Disease; Female; Humans; Male; Multicenter Studies as Topic; Neuropsychological Tests; Research Design; Selegiline; Vitamin E	1996
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:2 Topics: Activities of Daily Living; Adult; Aged; Antioxidants; Antiparkinson Agents; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome; Vitamin E	1997
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England journal of medicine, 1997, Apr-24, Volume: 336, Issue:17 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Disease Progression; Double-Blind Method; Drug Combinations; Female; Humans; Institutionalization; Male; Mental Status Schedule; Monoamine Oxidase Inhibitors; Proportional Hazards Models; Selegiline; Treatment Outcome; Vitamin E	1997
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Annals of neurology, 1998, Volume: 43, Issue:3 Topics: Aged; Antiparkinson Agents; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Selegiline; Vitamin E	1998
Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology, 1998, Volume: 50, Issue:6 Topics: Antioxidants; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Parkinson Disease; Selegiline; Vitamin E	1998
DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Annals of neurology, 1998, Volume: 44, Issue:3 Suppl 1 Topics: Antioxidants; Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E	1998
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology, 2001, Jun-26, Volume: 56, Issue:12 Topics: Aged; Double-Blind Method; Female; Gait; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Vitamin E	2001
[The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials]. Neurologia i neurochirurgia polska, 2001, Volume: 35, Issue:1 Suppl Topics: Adolescent; Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuroprotective Agents; Selegiline; Survival Rate; Vitamin E	2001
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. The American journal of pathology, 2014, Volume: 184, Issue:4 Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; alpha-Tocopherol; Antiparkinson Agents; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline	2014
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. Parkinsonism & related disorders, 2015, Volume: 21, Issue:3 Topics: Adult; Aged; Amyloid beta-Peptides; Antioxidants; Apolipoproteins E; Cognition Disorders; Cohort Studies; Cross-Sectional Studies; Female; Humans; Linear Models; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Peptide Fragments; Predictive Value of Tests; Selegiline; Severity of Illness Index; tau Proteins; Time Factors; Vitamin E	2015
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:5 Topics: alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Predictive Value of Tests; Selegiline; Treatment Outcome; Vitamin B 12	2018
Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. Parkinsonism & related disorders, 2022, Volume: 94 Topics: alpha-Tocopherol; Antiparkinson Agents; Humans; Parkinson Disease; Precision Medicine; Proteomics; Selegiline	2022

Other Studies

28 other study(ies) available for d-alpha tocopherol and selegiline

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Therapy of Parkinson's disease: are we at the end of the road? The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:6 Topics: Antiparkinson Agents; Dopamine Agents; Humans; India; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E	1992
Many researchers, few clinicians, using drug that may slow, even prevent, Parkinson's. JAMA, 1990, Sep-05, Volume: 264, Issue:9 Topics: Humans; Parkinson Disease; Selegiline; Vitamin E	1990
Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology, 1990, Volume: 40, Issue:9 Topics: Humans; Parkinson Disease; Phenethylamines; Selegiline; Vitamin E	1990
Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. Journal of neural transmission. Supplementum, 1990, Volume: 32 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biotransformation; Brain; Humans; In Vitro Techniques; Male; Mice; Monoamine Oxidase; Nervous System; Neurotoxins; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Inbred Strains; Selegiline; Vitamin E	1990
Deprenyl and the issue of neuroprotection. European neurology, 1994, Volume: 34, Issue:1 Topics: Antioxidants; Cell Survival; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Neurons; Parkinson Disease; Selegiline; Substantia Nigra; Vitamin E	1994
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5 Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E	1995
A 61-year-old man with Parkinson's disease. JAMA, 1996, Mar-06, Volume: 275, Issue:9 Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E	1996
Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. Journal of neuroscience research, 1996, Dec-15, Volume: 46, Issue:6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Survival; Dopamine; Dopamine Agents; Free Radicals; Gene Expression Regulation, Enzymologic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotoxins; PC12 Cells; Plasmids; Rats; Selegiline; Sensitivity and Specificity; Vitamin E	1996
Study design problems of DATATOP study analysis. Annals of neurology, 1996, Volume: 40, Issue:6 Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Selegiline; Vitamin E	1996
Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less. The New England journal of medicine, 1997, Apr-24, Volume: 336, Issue:17 Topics: Alzheimer Disease; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Selegiline; Vitamin E	1997
Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free radical biology & medicine, 1997, Volume: 23, Issue:4 Topics: Animals; Antioxidants; Benzoquinones; Cell Death; Cystine; Dithiothreitol; Glutamic Acid; Glutathione; Glutathione Reductase; Kinetics; L-Lactate Dehydrogenase; Oxidative Stress; PC12 Cells; Rats; Selegiline; Ubiquinone; Vitamin E	1997
Study suggests antioxidants slow decline in Alzheimer's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Jul-01, Volume: 54, Issue:13 Topics: Alzheimer Disease; Antioxidants; Disease Progression; Humans; Selegiline; Vitamin E	1997
Alpha-tocopherol and Alzheimer's disease. The New England journal of medicine, 1997, Aug-21, Volume: 337, Issue:8 Topics: Alzheimer Disease; Bias; Humans; Proportional Hazards Models; Selegiline; Survival Analysis; Vitamin E	1997
Alpha-tocopherol and Alzheimer's disease. The New England journal of medicine, 1997, Aug-21, Volume: 337, Issue:8 Topics: Aged; Alzheimer Disease; Cognition; Drug Therapy, Combination; Educational Status; Humans; Male; Selegiline; Vitamin E	1997
Selegiline and vitamin E in Alzheimer's disease. The Journal of family practice, 1997, Volume: 45, Issue:2 Topics: Aged; Alzheimer Disease; Disease Progression; Drug Combinations; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Reproducibility of Results; Selegiline; Treatment Outcome; Vitamin E	1997
Drug treatment for Alzheimer's disease. The Western journal of medicine, 1998, Volume: 168, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Indans; Male; Neuroprotective Agents; Piperidines; Selegiline; Vitamin E	1998
Advances in the treatment of Alzheimer's disease. Aging (Milan, Italy), 1998, Volume: 10, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Controlled Clinical Trials as Topic; Humans; Neuroprotective Agents; Nootropic Agents; Selegiline; Tacrine; Vitamin E	1998
Alzheimer's disease management. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 13 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Middle Aged; Piperidines; Selegiline; Tacrine; Vitamin E	1998
Pharmacological approaches to counter the toxicity of Dopa. Amino acids, 1998, Volume: 14, Issue:1-3 Topics: Animals; Benzothiazoles; Cells, Cultured; Cerebellum; Cytoplasmic Granules; Glutathione; Levodopa; Neuroprotective Agents; Pramipexole; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Selegiline; Thiazoles; Vitamin E	1998
The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biological psychiatry, 1999, Dec-15, Volume: 46, Issue:12 Topics: Animals; Antioxidants; Antipsychotic Agents; Delayed-Action Preparations; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluphenazine; Free Radicals; Male; Neuroprotective Agents; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Vitamin E	1999
Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Managed care interface, 2000, Volume: 13, Issue:1 Topics: Algorithms; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Caregivers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Donepezil; Drug Interactions; Estrogens; Female; Ginkgo biloba; Humans; Indans; Male; Managed Care Programs; Nootropic Agents; Patient Selection; Phytotherapy; Piperidines; Plants, Medicinal; Psychotropic Drugs; Quality of Health Care; Selegiline; Tacrine; Time Factors; Vitamin E	2000
Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Biochemical pharmacology, 2000, Sep-01, Volume: 60, Issue:5 Topics: Animals; Antioxidants; Dose-Response Relationship, Drug; Humans; Lipid Bilayers; Lipid Peroxidation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Selegiline; Swine; Vitamin E; X-Ray Diffraction	2000
A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life sciences, 2003, Apr-25, Volume: 72, Issue:23 Topics: alpha-Tocopherol; Animals; Benzofurans; Brain; Dopamine; In Vitro Techniques; Male; Monoamine Oxidase Inhibitors; Norepinephrine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Treatment Failure	2003
Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Medical hypotheses, 2004, Volume: 63, Issue:2 Topics: Acetylcarnitine; Alzheimer Disease; Brain; Cholinesterases; Cytidine Diphosphate Choline; Enzyme Activators; Humans; Meclofenoxate; Selegiline; Vitamin E	2004
Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:11 Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Alzheimer Disease; Caregivers; Conflict, Psychological; Cost of Illness; Decision Making; Family; Female; Humans; Male; Mental Status Schedule; Middle Aged; Professional-Family Relations; Selegiline; Spouses	2005
Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. Endocrine research, 2005, Volume: 31, Issue:3 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aging; Animals; Antioxidants; Blood Glucose; Body Weight; Deoxyguanosine; Diabetes Mellitus, Experimental; Disease Models, Animal; DNA Damage; Gliclazide; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidants; Oxidative Stress; Rats; Rats, Inbred Strains; Selegiline; Superoxide Dismutase; Vitamin A; Vitamin E	2005
Antioxidants and Alzheimer's disease: time to stop feeding vitamin E to dementia patients? International psychogeriatrics, 2007, Volume: 19, Issue:1 Topics: Aging; Alzheimer Disease; Antioxidants; Cognition Disorders; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative Stress; Selegiline; Vitamin E	2007